ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1471

Flare Incidence and Predictive Factors in a Population of Patients with Rheumatoid Arthritis Under Optimised Treatment with Adalimumab and Infliximab

Amara Pieren1, Dora Pascual-Salcedo2, Pilar Aguado3, Gema Bonilla4, Eugenio De Miguel5, Irene Monjo6, Laura Nuño3, Diana Peiteado3, Alejandro Villalba3, Enrique Moral Coro4, C. Tornero7, Patricia Bogas4, Alejandro Balsa3 and Chamaida Plasencia-Rodriguez4, 1Rheumatologyº, Hospital La Paz, Madrid, Spain, 2Immuno-Rheumatology Research group, La Paz University Hospital, Madrid, Spain, 3Rheumatology, La Paz University Hospital, Madrid, Spain, 4Hospital Universitario La Paz, Madrid, Spain, 5Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, 6Internal Medicine, Hospital Universitario La Paz, MADRID, Spain, 7Rheumatology, Rheumatology. La Paz University Hospital, Spain., Madrid, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Adalimumab, Biologic agents, infliximab and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:Anti-TNF has drastically changed the prognostic of the RA,carrying an important healthcare expense.This is why,optimisation seems a successful strategy that should not be linked to a worse become of our patientsÕ clinical evolution.

Methods: Observational study of the prospective cohort RA-Paz. Aim of the study:describe a population of patients with RA under optimised treatment with Adalimumab(Ada) or Infliximab(Ifx).Study the incidence of flares and establish predictive factors of flares at baseline and pre-optimization.All the patients diagnosed of RA under treatment with Ifx or Ada between Jan.2000 and Dec.2016 of the day-care unit,were included.Demographic data,clinical activity and blood sample results were collected at baseline,pre-optimization(pre-op)and at 3,6,9,12,18 and 24 months.Drug serum trough levels were measured under ELISA in each visit.Optimal range for Ifx was described as drug concentration between 1000- 4000 ng/ml and 1500- 5000 ng/ml for Ada.Optimisation was defined as drug use below standard dose.Flares were collected from the pre-op visit.Flare was described as clinical worsening which led to a therapeutic change or a DAS28>3.2 and DeltaDAS28>0,6.Predictive factors of flare at baseline and pre-op were evaluated with a uni and multivariate analysis.

Results: Of the 271 patients diagnosed of RA, 74 patients were optimised (44 under Ada and 30 under Ifx). During the 24 months after the pre-op visit,55,4%(41)of the patients presented at least one flare,with an average of 1,38 flares[1-5]. 53.7% of the patients,(22/41),were controlled with the adjustment of non biological treatment.Only 39,0%(16) of the patients,had to go back to the previous optimised dose and 7,3%(3)to the standard dose.88%(39/41)were controlled after the dose modification.104 flares were collected,33%(34) happened at the 3rd month and 20%(21) at 24th. In the population who presented flares, we observed a persistent higher DAS Vs the patients who never presented flares(DAS pre-op 3,20±1,16 Vs 2,26±0,59;DAS 24month 3,61±1,13Vs2,10±0,65;p=0,007). A least proportion of patients with flares were in supra-optimal range(13,3% with flares vs 26% without, p=0,007). At baseline, no clinical factors were predictive of flare. Nor were blood sample results. In contrast, a higher disease activity, measured by DAS pre-op(p=0,004),a worst EULAR answer(p=0,027) and not being in supra-optimal range(p=0,032),were statistically correlated with flares development at the univariate analysis. Time to the optimisation tended to the significance(OR=1,152; p=0.08). In the multivariate analysis, only a higher DAS pre-op(OR:2,00,[1,08-3,73])and being in optimal(OR:5,90, [1,38-25,2])and sub-optimal range(OR=6,05[1,28-28,7]), were independently correlated.

Conclusion: We noted a high proportion of flares in our cohort of optimised patietns. However, flares were controlled with dosage readjustment without needing a chanfe of the treatment. Independently correlated predictive factors for flares were a higher disease activity measured by DAS and not being in therapeutic range in the pre-optimisation visit.


Disclosure: A. Pieren, None; D. Pascual-Salcedo, None; P. Aguado, None; G. Bonilla, None; E. De Miguel, None; I. Monjo, None; L. Nuño, None; D. Peiteado, None; A. Villalba, None; E. Moral Coro, None; C. Tornero, Alexion Pharmaceuticals, Inc., 9; P. Bogas, None; A. Balsa, None; C. Plasencia-Rodriguez, None.

To cite this abstract in AMA style:

Pieren A, Pascual-Salcedo D, Aguado P, Bonilla G, De Miguel E, Monjo I, Nuño L, Peiteado D, Villalba A, Moral Coro E, Tornero C, Bogas P, Balsa A, Plasencia-Rodriguez C. Flare Incidence and Predictive Factors in a Population of Patients with Rheumatoid Arthritis Under Optimised Treatment with Adalimumab and Infliximab [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/flare-incidence-and-predictive-factors-in-a-population-of-patients-with-rheumatoid-arthritis-under-optimised-treatment-with-adalimumab-and-infliximab/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/flare-incidence-and-predictive-factors-in-a-population-of-patients-with-rheumatoid-arthritis-under-optimised-treatment-with-adalimumab-and-infliximab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology